Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Q3 net loss rises to $37.8 million from $23.3 million

Mixed Impact 3 of 5 earnings

Corbus reported a third-quarter 2026 net loss of $37.8 million, up from $23.3 million a year earlier, driven by a $15.0 million development milestone under its CSPC license. Net loss per share narrowed to $1.81 from $1.90, but the filing shows a higher share count of 20,837,787 weighted shares. The company had $115.3 million in cash and investments and says it expects this to fund operations into 2028.

Key points

  • Net loss of $37.8 million, or $1.81 per share, for the quarter ended September 30, 2026, versus $23.3 million, or $1.90 per share, a year earlier
  • Operating expenses rose $14.4 million to $38.8 million, including a $15.0 million development milestone under the CSPC licensing agreement
  • Cash, cash equivalents and investments totaled $115.3 million at September 30, 2026, which the company expects to fund operations into 2028
  • TEMPO-1 Phase 3 study of sutantatug envedotin began dosing in September 2026; CANYON-1 Phase 1b topline data for CRB-913 will be presented at ObesityWeek on November 15, 2026

The filing

CompanyCorbus Pharmaceuticals Holdings, Inc. (CRBP)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:08 AM ET
Accession number0001193125-26-454476

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.